Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure Biosciences share offering over-subscribed

The fund-raising process was a roaring success and enabled the company to, among other things, eliminate all variable-rate debt
Dollars
The company raised $5,101,049 in cash from the total offering

All five board members of Pressure BioSciences Inc (OTCMKTS:PBIO) put their hands in their pockets to support the pressure cycling technology (PCT) specialist's fund-raising.

The company announced the receipt of $769,667 in the final close of its $5mln private investment in public equity (PIPE) financing .

The final closing increased the total raised in the offering to $6,329,667, comfortably above the company's goal of $5mln. Pressure BioSciences netted $719,049 in cash from the final close and $5,101,049 in cash from the total offering.

Under the terms of the offer, the company issued senior secured convertible debentures with a fixed conversion price of $0.28 per restricted common share, and common stock purchase warrants exercisable into shares of restricted common stock at an exercise price of $0.40 per share.

Richard Schumacher, president and chief executive officer of Pressure BioSciences, said the cash raised had enabled the company to accomplish a number of key goals during the latter half of 2015 and the first three months of 2016. These include:

  1. the elimination of all variable-rate debt;

  2. the development of the new Barocycler NEP2320 Extreme, designed specifically for use in mass spectrometry sample preparation, including AB Sciex's SWATH-MS mass spectrometric system;

  3. the support of new marketing initiatives to potential customers worldwide that have already begun to show positive results through increased requests for instrument/consumable information and quotations);

  4. the ability to support multiple scientific collaborators, many of whom are considered key opinion leaders, whose studies readily highlight the advantages of the PCT platform to potential customers worldwide;

  5. the ability to strongly support the recently announced co-marketing agreement with SCIEX, a leader in life sciences analytical technologies worldwide.

“We are very pleased to have not only completed the $5mln financing, but to have completed it with approximately $1.3mln in over-subscriptions.  We thank all investors who participated in the offering for their faith and trust in the PBI Team and in our patented and enabling pressure cycling technology ... platform," Schumacher said.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 06 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use